H.C. Wainwright Downgrades Juniper Pharmaceuticals (JNP) to Neutral

August 19, 2016 8:48 AM EDT
Get Alerts JNP Hot Sheet
Price: $5.45 --0%

Rating Summary:
    1 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade JNP Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

H.C. Wainwright downgraded Juniper Pharmaceuticals (NASDAQ: JNP) from Buy to Neutral with a price target of $6.75. Analyst Ed Arce noted that after markets closed on August 17, Juniper announced in a terse release that the Phase 2b trial of its lead drug candidate, COL-1077 (10% lidocaine bioadhesive gel), failed to achieve its primary and secondary endpoints, and that based on these results, the company is discontinuing development of the product.

For an analyst ratings summary and ratings history on Juniper Pharmaceuticals click here. For more ratings news on Juniper Pharmaceuticals click here.

Shares of Juniper Pharmaceuticals closed at $5.75 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Downgrades

Related Entities

H.C. Wainwright

Add Your Comment